SCHEMBL24701025

SCHEMBL24701025

O=C(c1ccc(Cl)cc1)N1C[C@@H]2C[C@H]1CN2c1ccc([N+](=O)[O-])c2ncccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.64
MTOR P42345 1/20 0.64
SIRT2 Q8IXJ6 1/20 0.64
SLC6A7 Q99884 1/20 0.48
MAPT P10636 11/20 0.46
ALDH1A1 P00352 7/20 0.46
LMNA P02545 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
TNNI3 P19429 1/20 0.41
TNNT2 P45379 1/20 0.41
TNNC1 P63316 1/20 0.41
JMJD7 P0C870 1/20 0.40
CTSB P07858 4/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24701131 1.00 RAB9A (0.64) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL24790147 0.80 MTOR (0.72) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL19243666 0.80 MTOR (0.72) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL24790358 0.80 MTOR (0.72) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL24701119 0.79 MTOR (0.70) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL24700856 0.79 MTOR (0.70) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL26386902 0.78 MTOR (0.69) RAB9AMTORSIRT2MAPTALDH1A1
SCHEMBL26386905 0.78 MTOR (0.69) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL29943849 0.78 MTOR (1.00) RAB9AMTORSIRT2SLC6A7MAPT
SCHEMBL6267516 0.78 MTOR (1.00) RAB9AMTORSIRT2SLC6A7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402883-A1 COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION ARRAKIS THERAPEUTICS, INC. 2022-12-22 US disclosed
US-20220281860-A1 COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES ARRAKIS THERAPEUTICS, INC. 2022-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281860-A1 COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES NSUN3, NSUN2, POLRMT RAB9A 1919/4885MTOR 1869/4885SIRT2 1924/4885
US-20220402883-A1 COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION NSUN3, NSUN2, METTL16 RAB9A 2764/4885MTOR 1926/4885SIRT2 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.